Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Journal of the National Cancer Institute - 7 May 2008

Punglia Rinaa S, Burstein Harold J, Winer Eric P, Weeks Jane C

Abstract excerpt

BACKGROUND: Adjuvant endocrine treatment with aromatase inhibitors improves disease-free survival compared with tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer. This difference could be due to differences in tamoxifen metabolism because levels of endoxifen, the active tamoxifen metabolite, vary with the number of mutant alleles, including the *4 allele, of the gene encoding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Decision Support Techniques

Share to Neoplasms, Hormone-Dependent

Share to Postmenopause

Share to Selective Estrogen Receptor Modulators

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 18445827
DOI: 10.1093/jnci/djn100
PMCID: PMC2864146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.PMID 18445827Read ↗

Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling AnalysisSemantic proximity Read ↗

Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.Semantic proximity Read ↗

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Semantic proximity Read ↗

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?Semantic proximity Read ↗

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

Effect of CYP2D6 polymorphisms on breast cancer recurrence.Semantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.